CN108349943A - 杂环受限三环磺酰胺作为抗癌试剂 - Google Patents

杂环受限三环磺酰胺作为抗癌试剂 Download PDF

Info

Publication number
CN108349943A
CN108349943A CN201680063247.5A CN201680063247A CN108349943A CN 108349943 A CN108349943 A CN 108349943A CN 201680063247 A CN201680063247 A CN 201680063247A CN 108349943 A CN108349943 A CN 108349943A
Authority
CN
China
Prior art keywords
hydrogen
alkyl
optionally substituted
aryl
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680063247.5A
Other languages
English (en)
Chinese (zh)
Inventor
M·奥尔迈尔
N·扎瓦尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xi Naishanyikan Medical College
Original Assignee
Xi Naishanyikan Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xi Naishanyikan Medical College filed Critical Xi Naishanyikan Medical College
Publication of CN108349943A publication Critical patent/CN108349943A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201680063247.5A 2015-09-09 2016-09-08 杂环受限三环磺酰胺作为抗癌试剂 Pending CN108349943A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562216168P 2015-09-09 2015-09-09
US62/216,168 2015-09-09
PCT/US2016/050685 WO2017044567A1 (en) 2015-09-09 2016-09-08 Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents

Publications (1)

Publication Number Publication Date
CN108349943A true CN108349943A (zh) 2018-07-31

Family

ID=56940436

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680063247.5A Pending CN108349943A (zh) 2015-09-09 2016-09-08 杂环受限三环磺酰胺作为抗癌试剂

Country Status (6)

Country Link
US (1) US10221158B2 (enExample)
EP (1) EP3347350A1 (enExample)
JP (1) JP6966425B2 (enExample)
CN (1) CN108349943A (enExample)
CA (1) CA2997769A1 (enExample)
WO (1) WO2017044567A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114272378A (zh) * 2020-09-27 2022-04-05 四川大学华西医院 一种使cttnbp2nl功能缺失的试剂在制备治疗疾病的药物中的用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015138496A1 (en) 2014-03-11 2015-09-17 Icahn School Of Medicine At Mount Sinai Constrained tricyclic sulfonamides
WO2015138500A1 (en) 2014-03-11 2015-09-17 Icahn School Of Medicine At Mount Sinai Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents
JP6955485B2 (ja) 2015-09-09 2021-10-27 アイカーン スクール オブ メディスン アット マウント サイナイIcahn School of Medicine at Mt. Sinai 抗がん剤としての複素環式の限定された三環系スルホンアミド
WO2021150695A1 (en) * 2020-01-22 2021-07-29 Icahn School Of Medicine At Mount Sinai Constrained n-substituted tetrahydrobenzoazepine sulfonamides as anticancer and neuroprotective agents
US20230020161A1 (en) * 2020-02-28 2023-01-19 Rappta Therapeutics Oy Tricyclic Modulators of PP2A
US12398103B2 (en) * 2020-03-20 2025-08-26 Atux Iskay Llc 3-diarylmethylenes and uses thereof
KR20230145089A (ko) * 2021-02-08 2023-10-17 랍타 테라퓨틱스 오와이 단백질 포스파타제 2a(pp2a)의 치환된 사이클릭 조절인자 및 이를 사용하는 방법
EP4387962A4 (en) * 2021-08-18 2025-08-13 Atux Iskay Llc 2-DIARYLMETHYL-4-AMINOTETRAHYDROPYRAN DERIVATIVES AND RELATED COMPOUNDS USED AS ANTICANCER, ANTI-INFLAMMATORY, ANTIFIBROTIC, AND NEUROPROTECTIVE AGENTS
AU2023318912A1 (en) * 2022-08-04 2025-03-06 Rappta Therapeutics Oy Aromatic compounds for use as protein phosphatase 2a (pp2a) modulators

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634766A (en) 1983-10-31 1987-01-06 Merck Frosst Canada, Inc. 1,4-diaza-phenothiazines
GB8510680D0 (en) 1985-04-26 1985-06-05 Smith Kline French Lab Pyridine derivatives
US4882351A (en) 1987-10-14 1989-11-21 Roussel Uclaf Tricyclic compounds
US5834462A (en) 1993-07-26 1998-11-10 Eisai Co., Ltd. Tricyclic heterocyclic sulfonamide and sulfonic ester derivatives
EP0881220A4 (en) 1996-02-15 1999-04-21 Mitsubishi Chem Corp DIARYLSULTAME DERIVATIVES
US6333322B1 (en) 1996-03-13 2001-12-25 Eisai Co., Ltd. Nitrogen-containing tricyclic compounds and drugs containing the same
US6583138B1 (en) 1998-02-27 2003-06-24 Eisai Co., Ltd. Heterocyclic-ring condensed benzothiazine compound
CN1558907A (zh) 2000-09-20 2004-12-29 ���鹫˾ 作为双重组胺h1和h3促效剂或拮抗剂的取代咪唑
JP4428053B2 (ja) 2002-02-05 2010-03-10 味の素株式会社 ガバペンチン若しくはプレガバリンおよびn型カルシウムチャンネル拮抗剤を含有する医薬組成物
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
AU2005318465A1 (en) 2004-12-21 2006-06-29 Devgen N.V. Compounds with Kv4 ion channel activity
IT1362675B (it) 2005-03-15 2009-06-25 Menarini Internat Operations Luxembourg Sa N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche
JP4568361B2 (ja) 2005-04-22 2010-10-27 アラントス・ファーマシューティカルズ・ホールディング・インコーポレーテッド ジペプチジルペプチダーゼ−iv阻害剤
GB0508992D0 (en) 2005-05-03 2005-06-08 Novartis Ag Organic compounds
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
WO2008121859A1 (en) 2007-03-30 2008-10-09 Xenon Pharmaceuticals Inc. Methods of using tricyclic compounds in treating sodium channel-mediated diseases or conditions
CA2844985A1 (en) 2011-08-16 2013-02-21 Mt. Sinai School Of Medicine Tricyclic compounds as anticancer agents
US9701676B2 (en) 2012-08-24 2017-07-11 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
CN102942562B (zh) 2012-12-05 2014-10-01 天津市斯芬克司药物研发有限公司 一种苯并咪唑衍生物及其制备方法和应用
SG11201506450RA (en) 2013-02-19 2015-09-29 Icahn School Med Mount Sinai Tricyclic heterocycles as anticancer agents
WO2015138496A1 (en) 2014-03-11 2015-09-17 Icahn School Of Medicine At Mount Sinai Constrained tricyclic sulfonamides
WO2015138500A1 (en) 2014-03-11 2015-09-17 Icahn School Of Medicine At Mount Sinai Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents
WO2017024229A1 (en) 2015-08-06 2017-02-09 Icahn School Of Medecine At Mount Sinai Stereospecific process for 3-heterocyclylcycloaliphatic-1,2-diols
WO2017044575A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Constrained benzhydryl sulfonamides as anticancer and neuroprotective agents
JP6955485B2 (ja) 2015-09-09 2021-10-27 アイカーン スクール オブ メディスン アット マウント サイナイIcahn School of Medicine at Mt. Sinai 抗がん剤としての複素環式の限定された三環系スルホンアミド
WO2017044571A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Tricyclic sultam sulfonamides as anticancer and neuroprotective agents
WO2017044572A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Ring constrained diarylamino sulfonamides as anti-cancer agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114272378A (zh) * 2020-09-27 2022-04-05 四川大学华西医院 一种使cttnbp2nl功能缺失的试剂在制备治疗疾病的药物中的用途
CN114272378B (zh) * 2020-09-27 2023-06-23 四川大学华西医院 一种使cttnbp2nl功能缺失的试剂在制备治疗疾病的药物中的用途

Also Published As

Publication number Publication date
JP2018526416A (ja) 2018-09-13
US20180251444A1 (en) 2018-09-06
WO2017044567A1 (en) 2017-03-16
JP6966425B2 (ja) 2021-11-17
US10221158B2 (en) 2019-03-05
CA2997769A1 (en) 2017-03-16
EP3347350A1 (en) 2018-07-18

Similar Documents

Publication Publication Date Title
CN108349943A (zh) 杂环受限三环磺酰胺作为抗癌试剂
TWI791511B (zh) 細胞凋亡誘導劑
JP7007302B2 (ja) メニン-mll相互作用の阻害剤
CN108349961B (zh) 杂环受限三环磺酰胺作为抗癌试剂
EP3116860B1 (en) Sulfonamides derived from tricyclyl-2-aminocycloalkanols as anticancer agents
WO2017044575A1 (en) Constrained benzhydryl sulfonamides as anticancer and neuroprotective agents
CN106458916A (zh) 受限制的三环磺酰胺
WO2017044571A1 (en) Tricyclic sultam sulfonamides as anticancer and neuroprotective agents
JP2022521818A (ja) Prmt5インヒビター及びその使用
WO2017044572A1 (en) Ring constrained diarylamino sulfonamides as anti-cancer agents
CN116444427A (zh) 用于微管蛋白-src双靶点抑制剂的二芳基类化合物
WO2021150697A1 (en) N-substituted-3-tricyclyl piperidine derivatives as anticancer and neuroprotective agents
CN118119607A (zh) 作为抗癌、抗炎、抗纤维和神经保护剂的2-二芳基甲基-4-氨基四氢吡喃衍生物及相关化合物
CN113087743B (zh) 四氢大麻酚衍生物及其制备方法和在医药上的应用
HK1259348B (en) Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
WO2025091010A1 (en) Organic compounds
WO2021150700A1 (en) N-substituted-3-tricyclyl piperidine derivatives as anticancer and neuroprotective agents
CN117820340A (zh) Atr抑制剂及其用途
WO2025091037A1 (en) Organic compounds

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180731

WD01 Invention patent application deemed withdrawn after publication